Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
for Hypochondroplasia
8 locations incl. Oakland
Sponsor: QED Therapeutics, a BridgeBio company
Sex: All·Age: 3 - 18
Code: NCT07393373·Phase 2·Enrolling By Invitation